1 / 40

Antimicrobial resistance surveillance in Ireland

Antimicrobial resistance surveillance in Ireland. Results of invasive Staphylococcus aureus infection (blood) surveillance, 2009 **** Data as of 01/12/2010 ****. Ireland is a member of the European Antimicrobial Resistance Surveillance Network (EARS-Net).

toyah
Télécharger la présentation

Antimicrobial resistance surveillance in Ireland

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antimicrobial resistance surveillance in Ireland Results of invasive Staphylococcus aureus infection (blood) surveillance, 2009 **** Data as of 01/12/2010 **** Ireland is a member of the European Antimicrobial Resistance Surveillance Network (EARS-Net)

  2. EARS-Net S. aureus:Objective and case definition Objective: • To determine the proportions of S. aureus isolates from blood that are resistant to meticillin Case definition: • EARS-Net collects data on the first invasive isolate (from blood only) of S. aureus per patient per quarter

  3. Caveats in interpreting EARS-Net data • Care must be exercised when interpreting the raw figures, i.e. increases in numbers of isolates, as the numbers of laboratories reporting to EARS-Net has increased over the years • EARS-Net data does not distinguish clinically significant isolates from contaminants • If MRSA is isolated subsequent to MSSA within the same quarter, then that isolate is not counted (and similarly if MSSA is isolated subsequent to MSSA) [similarly for other pathogen-antibiotic resistance combinations]

  4. For further information on antimicrobial resistance and EARS-Net in Ireland, including quarterly and annual reports, plus reference/resource material on the individual pathogens under surveillance, see: http://www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/

  5. Antibiotic codes and abbreviations: CIP, Ciprofloxacin ERY, Erythromycin FUS, Fusidic Acid GEN, Gentamicin LIN, Lincomycin LNZ, Linezolid MET, Meticillin MUP, Mupirocin OXA, Oxacillin PEN, Penicillin RIF, Rifampicin TCY, Tetracycline TEI, Teicoplanin VAN, Vancomycin SAU, Staphylococcus aureus MRSA, Meticillin-Resistant S. aureus MSSA, Meticillin-Susceptible S. aureus VISA, Vancomycin-Intermediate S. aureus

  6. Numbers and proportions of S. aureus/MRSA from bacteraemia with 95% confidence Intervals (CI), 1999-2009

  7. S. aureus/MRSA bacteraemia trends, 1999-2009 Number of laboratories participating by year-end and quarter are indicated above the bars

  8. S. aureus/MRSA bacteraemia trends by quarter, 2002-2009 Number of laboratories participating by year-end indicated above the Q4 bars

  9. S. aureus/MRSA bacteraemia trends, 2002-2009: 4-quarterly moving average Number of laboratories participating by year-end indicated above the Q4 bars

  10. Numbers of S. aureus bacteraemia isolates and %MRSA by Hospital Network, 2009 Dub/M, Dublin Midlands; Dub-N, Dublin North; Dub-S, Dublin South; MW, Mid Western; NE, North Eastern; NW, North Western; S, Southern; SE South Eastern; W/NW, West/North Western

  11. Proportion of S. aureus bacteraemia isolates by Hospital Network, 2009 (n=1309)

  12. Numbers of S. aureus bacteraemia isolates, %MRSA and rates by Hospital Network, 2009 Dub/M, Dublin Midlands; Dub-N, Dublin North; Dub-S, Dublin South; MW, Mid Western; NE, North Eastern; NW, North Western; S, Southern; SE South Eastern; W/NW, West/North Western

  13. Numbers, proportions and rates of MRSA bacteraemia by hospital type, 2009 *Single speciality hospitals; ** Denominator data (BDU, Bed Days Used) not available; *** Complete denominator data not available; ^ includes all private hospitals/quarters for which no activity data were available Note: BDU provided by the Acute Services Team in the Business Intelligence Unit, Corporate Planning and Corporate Performance (CPCP) section of the Health Service Executive for acute hospitals and directly from the infection control/finance departments from private hospitals

  14. Rates of S. aureus bacteraemia isolates by Hospital Network*, 2009 (n=1253) * excludes private hospitals and other non-acute facilities

  15. Rates of MRSAbacteraemia isolates by Hospital Network, 2009 (n=350) * excludes private hospitals and other non-acute facilities

  16. Rates of MSSAbacteraemia isolates by Hospital Network, 2009 (n=903) * excludes private hospitals and other non-acute facilities

  17. Susceptibility data for S. aureus bacteraemia isolates, 2009 (n=1309)

  18. Susceptibility data for MRSAbacteraemia isolates, 2009 (n=355)

  19. Susceptibility data for MSSAbacteraemia isolates, 2009 (n=954)

  20. Antibiogram results for MRSA isolates referred to NMRSARL, 2009 (n=321) Data provided by National MRSA Reference Laboratory, St James’s Hospital

  21. Trends in proportion of gentamicin resistance among MRSA isolates^, 1999-2009 ^ Data from National MRSA Reference Laboratory; Changes in the numbers of participating laboratories are indicated above the bars

  22. Trends in proportion of fusidic acid resistance among MRSA isolates^, 1999-2009 ^ Data from National MRSA Reference Laboratory; Changes in the numbers of participating laboratories are indicated above the bars

  23. Statistical Process Charts • Assume proportion or rate stable over time (i.e. in control) • Mean calculated from data for quarters (data points) up to the previous quarter, i.e. excluding latest quarter • Warning limits and action limits are equal to 2 and 3 Standard Deviations (SD), respectively • These are used to determine if: • the trends in proportions or rates are behaving as expected, i.e. the process is in control. The variation observed here is due to chance (common cause or natural variation) or • the trends are not behaving as expected and something unusual is happening, i.e. the process is out of control. The variation observed here is unlikely to be due to chance alone. Special circumstances are more likely to operate (special cause variation) warranting further investigations

  24. Statistical Process Charts Special cause variation occurs if: • One value above or below the action limits (±3SD) • 3 consecutive values between upper warning and action limits (or lower limits) • 5 consecutive values in top or bottom 2/3 (between 1 and 3 SD, or -1 and -3 SD) • 13 consecutive values in top or bottom middle 1/3 (between mean and 1 SD, or mean and -1 SD) • 8 consecutive values on the same side of the mean • 12 of 14 consecutive values on same side of the mean • 8 consecutive values either increasing or decreasing • Cyclic or periodic behaviour

  25. Statistical Process ChartNational MRSA proportions: P-Chart Mean proportion calculated from data for Q1 2002-Q3 2009; UWL and LWL, Upper and Lower Warning Limits; UAL and LAL (±2 Standard Deviations), Upper and Lower Action Limits (±3 Standard Deviations)

  26. Statistical Process Chart National MRSA rates: U-Chart Mean rate calculated from data for Q1 2004-Q3 2009; UWL and LWL, Upper and Lower Warning Limits (±2 Standard Deviations); UAL and LAL, Upper and Lower Action Limits (±3 Standard Deviations)

  27. Statistical Process Charts P-chart: • The proportion of MRSA bacteraemia was above its upper control limit in Q2 2002, Q2 2003 and Q3 2006 and below its lower control limit for Q4 2007 and Q2 2008–Q4 2009. These indicate that the process is out of control - if true, the former represents a worsening situation and the latter an improving situation regarding %MRSA U-chart • The rate of MRSA bacteraemia was above its upper control limit in Q2 2005 and below its lower control limit for Q2 2008–Q4 2009, (except for Q1 2008) indicating that out of control - if true, the former represents a worsening situation and the latter an improving situation regarding %MRSA Worsening/improving situations warrant further investigation to determine reasons why

  28. Rates of S. aureus and MRSA bacteraemia, 2004-2009 1 Acute hospitals only (Total hospitals = Total acute hospitals in Ireland) 2 Bed Days Used (BDU) provided by the Acute Services Team in the Business Intelligence Unit, Corporate Planning and Corporate Performance (CPCP) section of the Health Service Executive for acute public hospitals and directly from the infection control/finance departments from acute private hospitals 3 Per 1,000 BDU: for 2004 and 2005, rates calculated using data from acute public hospitals only; for the period 2006-2009, rates calculated using data from all public and private acute hospitals for which both numerator (MRSA isolates) and denominator ( BDU) data available 4 Data from acute public hospitals only

  29. Vancomycin-Intermediate S. aureus (VISA) reports from EARSS in 2009* • In 2009, no MRSA isolates with reduced susceptibility to vancomycin were detected by the Etest macromethod • In 2006, two VISA isolates were detected, which were the first reports of VISA from EARSS in Ireland: • both were confirmed as VISA by CDC • one was shown to be VISA and the other to be h-VISA by population analysis profiling (PAP) studies *Data from the National MRSA Reference Laboratory, where all EARSS MRSA isolates submitted by participating laboratories are tested for reduced susceptibility to vancomycin

  30. Age distribution of patients with MRSA and MSSA bacteraemia in 2009

  31. Age-specific incidence rates of MRSA and MSSA bacteraemia in 2009 ASIR, Age-Specific Incidence Rate (per 100,000 population)

  32. Age and sex distribution of patients with MRSA bacteraemia in 2009

  33. Age and sex-specific incidence rates of MRSA bacteraemia in 2009 ASIR, Age-Specific Incidence Rate (per 100,000 population)

  34. Age and sex distribution of patients with MSSA bacteraemia in 2009

  35. Age and sex-specific incidence rates of MSSA bacteraemia in 2009 ASIR, Age-Specific Incidence Rate (per 100,000 population)

  36. Mean, median, mode and range of ages of patients with S. aureus (MRSA and MSSA) bacteraemia in 2009 The difference in median ages for patients with MRSA and MSSA bacteraemia is significant as the confidence intervals do not overlap

  37. Relative risk of developing MRSA bacteraemia associated with age in 2009 In patients with laboratory-confirmed S. aureus bacteraemia in 2009, the probability that the infecting organism was MRSA as compared to MSSA was approximately1.7-times greater in patients aged ≥65years than in those aged <65 years

  38. Sex distribution of patients with S. aureus (MRSA and MSSA) bacteraemia in 2009 In patients with laboratory-confirmed S. aureus bacteraemia in 2009, males were approximately 1.8-times more likely to get an infection (2.1-times for MRSA and 1.8-times for MSSA) than females. These findings were significant (P<0.0001)

  39. Distribution of MRSA in EARSS/EARS-Net countries in 2009 Map downloaded from: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 20/12/2010

  40. Distribution of MRSA in EARSS countries in 2008 Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009

More Related